2018核苷类药物在乙型肝炎后肝硬化治疗中的应用与疗效

3613392

　　[摘要] 目的 ?u价恩替卡韦（ETV）、替诺福韦（TDF）治疗乙型肝炎后肝硬化的临床疗效。方法 方便选取该院2016年1―6月收治的100例乙型肝炎后肝硬化患者随机分为A、B两组（各50例），A组给予ETV 0.5 mg/d，B组给予TDF300 mg/d，对比两组服药0、3、6、9、12个月的病毒载量情况、血清生化指标。结果 治疗3，6，9，12个月后HBV DNA数量均得到明显改善（P /6/view-10705711.htm
　　[关键词] 核苷类药物；乙肝肝硬化；病毒载量情况；血清生化指标
　　[中图分类号] R512 [文献标识码] A [文章编号] 1674-0742（2018）01（c）-0121-03
　　[Abstract] Objective This paper tries to evaluate the clinical efficacy of entecavir （ETV） and tenofovir （TDF） in the treatment of post-hepatitis B cirrhosis. Methods 100 cases of hepatitis B of patients with liver cirrhosis in this hospital were treated from January 2016 to June 2016 were randomly divided into group A， B（each with 50 cases）， group A was given ETV 0.5 mg/d， group B was given TDF300 mg/d， 0， 3， 6， 9， 12 months of viral load， serum biochemical indexes of the two groups were compared. Results After 3， 6， 9， 12 months treatment， HBV DNA were significantly improved（P